- Home
- SVRA vs ESPR Comparison
SVRA vs ESPR Comparison
Compare SVRA & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- ESPR
- Stock Information
- Founded
- SVRA 2007
- ESPR 2008
- Country
- SVRA United States
- ESPR United States
- Employees
- SVRA N/A
- ESPR N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- ESPR Health Care
- Exchange
- SVRA Nasdaq
- ESPR Nasdaq
- Market Cap
- SVRA 527.2M
- ESPR 534.3M
- IPO Year
- SVRA N/A
- ESPR 2013
- Fundamental
- Price
- SVRA $3.60
- ESPR $2.52
- Analyst Decision
- SVRA Buy
- ESPR Buy
- Analyst Count
- SVRA 8
- ESPR 6
- Target Price
- SVRA $6.63
- ESPR $6.50
- AVG Volume (30 Days)
- SVRA 1.1M
- ESPR 8.8M
- Earning Date
- SVRA 11-11-2025
- ESPR 11-06-2025
- Dividend Yield
- SVRA N/A
- ESPR N/A
- EPS Growth
- SVRA N/A
- ESPR N/A
- EPS
- SVRA N/A
- ESPR N/A
- Revenue
- SVRA N/A
- ESPR $268,125,000.00
- Revenue This Year
- SVRA N/A
- ESPR $13.05
- Revenue Next Year
- SVRA N/A
- ESPR N/A
- P/E Ratio
- SVRA N/A
- ESPR N/A
- Revenue Growth
- SVRA N/A
- ESPR N/A
- 52 Week Low
- SVRA $1.89
- ESPR $0.69
- 52 Week High
- SVRA $4.30
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- SVRA 61.30
- ESPR 51.82
- Support Level
- SVRA $3.35
- ESPR $2.44
- Resistance Level
- SVRA $3.53
- ESPR $2.75
- Average True Range (ATR)
- SVRA 0.13
- ESPR 0.20
- MACD
- SVRA -0.03
- ESPR -0.04
- Stochastic Oscillator
- SVRA 72.31
- ESPR 26.58
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.